Trazpiroben
# Trazpiroben

Trazpiroben (developmental code name TAK-906) is a dopamine antagonist drug which was under development for the treatment of gastroparesis. It acts as a peripherally selective dopamine $D_2$ and $D_3$ receptor antagonist. The drug has been found to strongly increase prolactin levels in humans, similarly to other peripherally selective $D_2$ receptor antagonists like domperidone. Clinical development of trazpiroben was discontinued before April 2022. Trazpiroben was originated by Altos Therapeutics and was under development by Takeda Oncology.

